4月27日,创新药龙头百济神州宣布了今年第一笔授权交易。 根据公告,百济神州的全资子公司广州百济神州生物制药有限公司(以下简称百济神州广州)与华辉安健(北京)生物科技有限公司(以下简称华辉安健)签订了一份《独家选择权、许可与合作协议》(以下简称《合作协议》)。 双方的合作围绕华辉安健在研的靶向PD- 1、CTLA- 4及VEGF-A的三特异性化合物(包括HH160)及包含该等化合物的任何产品...
Source Link4月27日,创新药龙头百济神州宣布了今年第一笔授权交易。 根据公告,百济神州的全资子公司广州百济神州生物制药有限公司(以下简称百济神州广州)与华辉安健(北京)生物科技有限公司(以下简称华辉安健)签订了一份《独家选择权、许可与合作协议》(以下简称《合作协议》)。 双方的合作围绕华辉安健在研的靶向PD- 1、CTLA- 4及VEGF-A的三特异性化合物(包括HH160)及包含该等化合物的任何产品...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.